Login to Your Account



Financings Roundup

Vical Adds $50M Publicly for Allovectin, HSV-2 Programs

By Karen Pihl-Carey
BioWorld Today Contributing Writer

Monday, January 9, 2012

As Vical Inc. ramps up for a potential biologics license application filing and the commercialization of its cancer immunotherapy Allovectin – and with promising data from a preclinical herpes simplex virus type 2 (HSV-2) program – the San Diego-based company priced a $50 million public offering on Friday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription